The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly's weight-loss drug Zepbound and its ...

Eli Lilly escalates its crackdown on unauthorized tirzepatide copies, filing lawsuits against four compounders accused of ...

Mochi Health Corp, Fella Health and Delilah, Willow Health Services, and Henry Meds are the named companies in Eli Lilly’s ...

Lilly's Mounjaro and Zepbound, which share the same generic drug (tirzepatide), are already giving Ozempic and Wegovy, which also share the same generic (semaglutide), a run for their money.

Where will Eli Lilly be in five years? Lilly's Mounjaro and Zepbound, which share the same generic drug (tirzepatide), are already giving Ozempic and Wegovy, which also share the same generic ...

Eli Lilly (NYSE:LLY) just pre-announced a $1.57 billion pre-tax charge related to acquired in-process R&D, which is expected to weigh down Q1 2025 earnings by $1.57 per share. The Indiana-based ...

Where will Eli Lilly be in five years ... retatrutide holds the potential to deliver more weight loss than tirzepatide. Lilly plans to report results from a phase 3 study of the drug later ...

Eli Lilly and Company is the world's most valuable Pharma thanks to tirzepatide, a groundbreaking GLP-1 weight-loss and Type 2 Diabetes drug, marketed and sold as Zepbound / Mounjaro. Hims & Hers ...

Eli Lilly, for its part, sells tirzepatide as Mounjaro and Zepbound for diabetes and obesity, respectively. In addition, retatrutide is Lilly’s next-generation weight loss candidate. In a phase ...